Ischemic stroke is a leading cause of mortality and morbidity worldwide. Numerous therapeutic studies, including
stem cell therapy, have been explored in order to find the possible approach treating cerebral ischemia effectively.
However, massive grafted-cell death and low survival rate made us pessimistic about the widespread application of stem
cell therapy. The approach of preconditioning stem cells became an attractive option due to its high cell viability after
transplantation. In this review, we focused on preconditioning stem cells via cytokines, chemical drugs and other factors
including interleukin 6 (IL-6), lipopolysaccharide (LPS), minocycline, melatonin and hypoxia to increase grafted stem cell
survival, proliferation, migration to ischemic peri-focal area and ultimately improve neurobehavioral outcomes. We explored
the underlying therapeutic efficacy of preconditioning stem cells as well as possible mechanisms and potential
risks. Finally, we discussed the prospects of the application of cell-based therapy in clinical patients with ischemic stroke.